同种异体肾移植排斥患者血清sFas和sFasL水平的临床观察

The clinical observation of serum soluble Fas and soluble Fas ligand levels in renal allograft rejection patients

目的 观察肾同种移植急性排斥患者血清可溶性Fas(sFas)和sFas配体(sFasL)的水平及临床意义。 方法 采用酶联免疫吸附试验(ELISA)分别对健康对照组及实验组透析前后sFas、sFasL进行检测。结果 对 照组sFas为(256.8±72.0)ng/L,sFasL为(227.9±65.9)ng/L;实验组透析前后sFas分别为(1225.7±467.6) ng/L、(1225.8±464.0)ng/L,sFasL分别为(227.9±147.2)ng/L、(226.9±109.6)ng/L。实验组与对照组的 sFas比较差异有显著性(P<0.01),而sFasL比较差异无显著性(P>0.05)。结论 sFas在排异的病理反应过 程中参与了细胞凋亡的抑制,透析并不能改善Fas FasL介导的细胞凋亡。

Objective To observe the serum levels and clinical significance of solubel Fas (sFas) and soluble Fas ligand (sFasL) in patients with acute allograft rejection after kidney transplantation. Methods sFas and sFasL concentrations of control group and test group were measured by ELISA. Sera of the test group were determined before and after dialysis. Results sFas and sFasL concentrations in control group were ( 256.8±72.0)ng/L and ( 227.9 ±65.9)ng/L respectively; In patients before and after dialysis, sFas concentration was ( 1 225.7 ±467.6)ng/L and ( 1 225.8 ±464.0)ng/L respectively, sFasL concentration was ( 227.9 ±147.2)ng/L and ( 226.9 ±109.6)ng/L respectively. There was statistically significant difference in sFas concentration between control and test group (P <0.01). There was no significant difference of sFasL between two groups (P >0.05). Conclusions The high sFas level in serum plays an inhibition role in apoptosis, and dialysis can not improve Fas-FasL mediated apoptosis.